525 related articles for article (PubMed ID: 22908275)
1. Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2.
Greulich H; Kaplan B; Mertins P; Chen TH; Tanaka KE; Yun CH; Zhang X; Lee SH; Cho J; Ambrogio L; Liao R; Imielinski M; Banerji S; Berger AH; Lawrence MS; Zhang J; Pho NH; Walker SR; Winckler W; Getz G; Frank D; Hahn WC; Eck MJ; Mani DR; Jaffe JD; Carr SA; Wong KK; Meyerson M
Proc Natl Acad Sci U S A; 2012 Sep; 109(36):14476-81. PubMed ID: 22908275
[TBL] [Abstract][Full Text] [Related]
2. Mutational landscape and characteristics of ERBB2 in non-small cell lung cancer.
Wei XW; Gao X; Zhang XC; Yang JJ; Chen ZH; Wu YL; Zhou Q
Thorac Cancer; 2020 Jun; 11(6):1512-1521. PubMed ID: 32291971
[TBL] [Abstract][Full Text] [Related]
3. Allele-Specific Role of ERBB2 in the Oncogenic Function of EGFR L861Q in EGFR-Mutant Lung Cancers.
Sato H; Offin M; Kubota D; Yu HA; Wilhelm C; Toyooka S; Somwar R; Kris MG; Ladanyi M
J Thorac Oncol; 2021 Jan; 16(1):113-126. PubMed ID: 33038514
[TBL] [Abstract][Full Text] [Related]
4. Lung cancer: intragenic ERBB2 kinase mutations in tumours.
Stephens P; Hunter C; Bignell G; Edkins S; Davies H; Teague J; Stevens C; O'Meara S; Smith R; Parker A; Barthorpe A; Blow M; Brackenbury L; Butler A; Clarke O; Cole J; Dicks E; Dike A; Drozd A; Edwards K; Forbes S; Foster R; Gray K; Greenman C; Halliday K; Hills K; Kosmidou V; Lugg R; Menzies A; Perry J; Petty R; Raine K; Ratford L; Shepherd R; Small A; Stephens Y; Tofts C; Varian J; West S; Widaa S; Yates A; Brasseur F; Cooper CS; Flanagan AM; Knowles M; Leung SY; Louis DN; Looijenga LH; Malkowicz B; Pierotti MA; Teh B; Chenevix-Trench G; Weber BL; Yuen ST; Harris G; Goldstraw P; Nicholson AG; Futreal PA; Wooster R; Stratton MR
Nature; 2004 Sep; 431(7008):525-6. PubMed ID: 15457249
[TBL] [Abstract][Full Text] [Related]
5. Activating ERBB4 mutations in non-small cell lung cancer.
Kurppa KJ; Denessiouk K; Johnson MS; Elenius K
Oncogene; 2016 Mar; 35(10):1283-91. PubMed ID: 26050618
[TBL] [Abstract][Full Text] [Related]
6. Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors.
Thomas RK; Greulich H; Yuza Y; Lee JC; Tengs T; Feng W; Chen TH; Nickerson E; Simons J; Egholm M; Rothberg JM; Sellers WR; Meyerson ML
Cold Spring Harb Symp Quant Biol; 2005; 70():73-81. PubMed ID: 16869740
[TBL] [Abstract][Full Text] [Related]
7. ERBB2 kinase domain mutation in the lung squamous cell carcinoma.
Lee JW; Soung YH; Kim SY; Nam SW; Park WS; Wang YP; Jo KH; Moon SW; Song SY; Lee JY; Yoo NJ; Lee SH
Cancer Lett; 2006 Jun; 237(1):89-94. PubMed ID: 16029927
[TBL] [Abstract][Full Text] [Related]
8. Non-small-cell lung cancer and Ba/F3 transformed cells harboring the ERBB2 G776insV_G/C mutation are sensitive to the dual-specific epidermal growth factor receptor and ERBB2 inhibitor HKI-272.
Shimamura T; Ji H; Minami Y; Thomas RK; Lowell AM; Shah K; Greulich H; Glatt KA; Meyerson M; Shapiro GI; Wong KK
Cancer Res; 2006 Jul; 66(13):6487-91. PubMed ID: 16818618
[TBL] [Abstract][Full Text] [Related]
9. EGFR, ERBB2, and KRAS mutations in Korean non-small cell lung cancer patients.
Bae NC; Chae MH; Lee MH; Kim KM; Lee EB; Kim CH; Park TI; Han SB; Jheon S; Jung TH; Park JY
Cancer Genet Cytogenet; 2007 Mar; 173(2):107-13. PubMed ID: 17321325
[TBL] [Abstract][Full Text] [Related]
10. EGFR and ERBB2 Germline Mutations in Chinese Lung Cancer Patients and Their Roles in Genetic Susceptibility to Cancer.
Lu S; Yu Y; Li Z; Yu R; Wu X; Bao H; Ding Y; Shao YW; Jian H
J Thorac Oncol; 2019 Apr; 14(4):732-736. PubMed ID: 30610926
[TBL] [Abstract][Full Text] [Related]
11. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
12. Actionable Activating Oncogenic ERBB2/HER2 Transmembrane and Juxtamembrane Domain Mutations.
Pahuja KB; Nguyen TT; Jaiswal BS; Prabhash K; Thaker TM; Senger K; Chaudhuri S; Kljavin NM; Antony A; Phalke S; Kumar P; Mravic M; Stawiski EW; Vargas D; Durinck S; Gupta R; Khanna-Gupta A; Trabucco SE; Sokol ES; Hartmaier RJ; Singh A; Chougule A; Trivedi V; Dutt A; Patil V; Joshi A; Noronha V; Ziai J; Banavali SD; Ramprasad V; DeGrado WF; Bueno R; Jura N; Seshagiri S
Cancer Cell; 2018 Nov; 34(5):792-806.e5. PubMed ID: 30449325
[TBL] [Abstract][Full Text] [Related]
13. EXEL-7647 inhibits mutant forms of ErbB2 associated with lapatinib resistance and neoplastic transformation.
Trowe T; Boukouvala S; Calkins K; Cutler RE; Fong R; Funke R; Gendreau SB; Kim YD; Miller N; Woolfrey JR; Vysotskaia V; Yang JP; Gerritsen ME; Matthews DJ; Lamb P; Heuer TS
Clin Cancer Res; 2008 Apr; 14(8):2465-75. PubMed ID: 18413839
[TBL] [Abstract][Full Text] [Related]
14. Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers.
Roskoski R
Pharmacol Res; 2019 Jan; 139():395-411. PubMed ID: 30500458
[TBL] [Abstract][Full Text] [Related]
15. EGFR and erbB2 mutation status in Japanese lung cancer patients.
Sasaki H; Shimizu S; Endo K; Takada M; Kawahara M; Tanaka H; Matsumura A; Iuchi K; Haneda H; Suzuki E; Kobayashi Y; Yano M; Fujii Y
Int J Cancer; 2006 Jan; 118(1):180-4. PubMed ID: 16003726
[TBL] [Abstract][Full Text] [Related]
16. Constitutive asymmetric dimerization drives oncogenic activation of epidermal growth factor receptor carboxyl-terminal deletion mutants.
Park AK; Francis JM; Park WY; Park JO; Cho J
Oncotarget; 2015 Apr; 6(11):8839-50. PubMed ID: 25826094
[TBL] [Abstract][Full Text] [Related]
17. Activating mutation in the catalytic domain of c-kit elicits hematopoietic transformation by receptor self-association not at the ligand-induced dimerization site.
Tsujimura T; Hashimoto K; Kitayama H; Ikeda H; Sugahara H; Matsumura I; Kaisho T; Terada N; Kitamura Y; Kanakura Y
Blood; 1999 Feb; 93(4):1319-29. PubMed ID: 9949175
[TBL] [Abstract][Full Text] [Related]
18. The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272.
Minami Y; Shimamura T; Shah K; LaFramboise T; Glatt KA; Liniker E; Borgman CL; Haringsma HJ; Feng W; Weir BA; Lowell AM; Lee JC; Wolf J; Shapiro GI; Wong KK; Meyerson M; Thomas RK
Oncogene; 2007 Jul; 26(34):5023-7. PubMed ID: 17311002
[TBL] [Abstract][Full Text] [Related]
19. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.
Arcila ME; Chaft JE; Nafa K; Roy-Chowdhuri S; Lau C; Zaidinski M; Paik PK; Zakowski MF; Kris MG; Ladanyi M
Clin Cancer Res; 2012 Sep; 18(18):4910-8. PubMed ID: 22761469
[TBL] [Abstract][Full Text] [Related]
20. ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies.
Chuang JC; Stehr H; Liang Y; Das M; Huang J; Diehn M; Wakelee HA; Neal JW
J Thorac Oncol; 2017 May; 12(5):833-842. PubMed ID: 28167203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
